Imaging the myocardial microcirculation post-myocardial infarction

Current Heart Failure Reports

Volumn 9, Issue 4, 2012, Pages 282-292

  White, Steven K ^a   Hausenloy, Derek J ^a,b   Moon, James C ^b,c  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Hatter Cardiovascular Institute   (United Kingdom)

Author keywords

Cardiovascular; Cardiovascular imaging techniques; Intramyocardial haemorrhage; Microcirculation; Microvascular dysfunction; Microvascular obstruction; Myocardial contrast echocardiography; No reflow

Indexed keywords

ADENOSINE; DIPYRIDAMOLE; ECHO CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICORANDIL; VERAPAMIL;

ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CONTRAST ECHOCARDIOGRAPHY; CONTRAST ENHANCEMENT; ELECTROCARDIOGRAM; FIBRINOLYTIC THERAPY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE BLOOD FLOW; HEART VENTRICLE REMODELING; HUMAN; HYPEREMIA; INTRAMYOCARDIAL HEMORRHAGE; MICROBUBBLE; MICROCIRCULATION; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; POSITRON EMISSION TOMOGRAPHY; REPERFUSION INJURY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

CARDIOTONIC AGENTS; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MICROCIRCULATION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VENTRICULAR REMODELING;

EID: 84872190590     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0111-y     Document Type: Article

References (105)

1. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med. 2007;356(8):830-40.
2. Chilian WM. Coronary microcirculation in health and disease. Summary of an NHLBI workshop. Circulation. 1997;95(2):522-8. (Pubitemid 27056222)
3. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357(11):1121-35.
4. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54(6):1496-508.
5. Kloner RA. No-reflow phenomenon: maintaining vascular integrity. J Cardiovasc Pharmacol Ther. 2011;16(3-4):244-50.
6. Kloner RA, Rude RE, Carlson N, et al. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first? Circulation. 1980;62 (5):945-52.
7. Reffelmann T, Kloner RA. Microvascular reperfusion injury: rapid expansion of anatomic no-reflow during reperfusion in the rabbit. Am J Physiol Heart Circ Physiol. 2002;283(3):H1099-107.
8. Schwartz BG, Kloner RA. Coronary no-reflow. J Mol Cell Cardiol. 2012;52(4):873-82.
9. Heusch G, Kleinbongard P, Bose D, et al. Coronary microembolization: from bedside to bench and back to bedside. Circulation. 2009;120(18):1822-36.
10. Bahrmann P, Werner GS, Heusch G, et al. Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris undergoing elective percutaneous coronary interventions. Circulation. 2007;115(5):600-8. (Pubitemid 46226170)
11. Ozaki Y, Tanaka A, Tanimoto T, et al. Thin-cap fibroatheroma as high-risk plaque for microvascular obstruction in patients with acute coronary syndrome. Circ Cardiovasc Imaging. 2011;4 (6):620-7.
12. Limbruno U, De Carlo M, Pistolesi S, et al. Distal embolization during primary angioplasty: histopathologic features and predictability. Am Heart J. 2005;150(1):102-8. (Pubitemid 41097435)
13. Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008;358(6):557-67.
14. Barbash GI, Roth A, Hod H, et al. Rapid resolution of ST elevation and prediction of clinical outcome in patients undergoing thrombolysis with alteplase (recombinant tissue-Type plasminogen activator): results of the Israeli Study of Early Intervention in Myocardial Infarction. Br Heart J. 1990;64 (4):241-7. (Pubitemid 20307767)
15. Zeymer U, Schroder R, Tebbe U, et al. Non-invasive detection of early infarct vessel patency by resolution of ST-segment elevation in patients with thrombolysis for acute myocardial infarction; results of the angiographic substudy of the Hirudin for Improvement of Thrombolysis (HIT)-4 trial. Eur Heart J. 2001;22(9):769-75.
16. Syed MA, Borzak S, Asfour A, et al. Single lead ST-segment recovery: a simple, reliable measure of successful fibrinolysis after acute myocardial infarction. Am Heart J. 2004;147 (2):275-80.
17. Schroder R, Dissmann R, Bruggemann T, et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol. 1994;24(2):384-91.
18. de Lemos JA, Antman EM, Giugliano RP, et al. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators. Am J Cardiol. 2000;85(3):299-304.
19. de Lemos JA, Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol. 2001;38(5):1283-94.
20. van't Hof AW, Liem A, de Boer MJ, Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lancet. 1997;350(9078):615-9. (Pubitemid 27367794)
21. Feldman LJ, Coste P, Furber A, et al. Incomplete resolution of ST-segment elevation is a marker of transient microcirculatory dysfunction after stenting for acute myocardial infarction. Circulation. 2003;107(21):2684-9. (Pubitemid 36667241)
22. Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-Term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol. 2000;36(4):1202-9.
23. Brener SJ, Moliterno DJ, Aylward PE, et al. Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study. Eur Heart J. 2008;29(9):1127-35.
24. Henriques JP, Zijlstra F, van't Hof AW, et al. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation. 2003;107(16):2115-9. (Pubitemid 36532193)
25. Gibson CM, Murphy SA, Rizzo MJ, et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation. 1999;99(15):1945-50.
26. van't Hof AW, Liem A, Suryapranata H, et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation. 1998;97(23):2302-6. (Pubitemid 28280383)
27. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-Term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 2002;105(16):1909-13.
28. Ambrosio G, Weisman HF, Mannisi JA, Becker LC. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation. 1989;80(6):1846-61.
29. Kaul S. Coronary angiography cannot be used to assess myocardial perfusion in patients undergoing reperfusion for acute myocardial infarction. Heart. 2001;86(5):483-4. (Pubitemid 32999851)
30. Hayat SA, Senior R. Myocardial contrast echocardiography in ST elevation myocardial infarction: ready for prime time? Eur Heart J. 2008;29(3):299-314.
31. Kaul S. Myocardial contrast echocardiography: a 25-year retrospective. Circulation. 2008;118(3):291-308.
32. Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation. 1992;85(5):1699-705.
33. Iwakura K, Ito H, Kawano S, et al. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol. 2001;38(2):472-7. (Pubitemid 32721776)
34. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996;93(2):223-8. (Pubitemid 26031478)
35. Greaves K, Dixon SR, Fejka M, et al. Myocardial contrast echocardiography is superior to other known modalities for assessing myocardial reperfusion after acute myocardial infarction. Heart. 2003;89(2):139-44.
36. Galiuto L, Garramone B, Scara A, et al. The extent of microvascular damage during myocardial contrast echocardiography is superior to other known indexes of post-infarct reperfusion in predicting left ventricular remodeling: results of the multicenter AMICI study. J Am Coll Cardiol. 2008;51(5):552-9.
37. Jeetley P, Swinburn J, Hickman M, et al. Myocardial contrast echocardiography predicts left ventricular remodelling after acute myocardial infarction. J Am Soc Echocardiogr. 2004;17 (10):1030-6. (Pubitemid 39273479)
38. Bolognese L, Carrabba N, Parodi G, et al. Impact of microvascular dysfunction on left ventricular remodeling and long-Term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation. 2004;109(9):1121-6. (Pubitemid 38332616)
39. Dwivedi G, Janardhanan R, Hayat SA, et al. Prognostic value of myocardial viability detected by myocardial contrast echocardiography early after acute myocardial infarction. J Am Coll Cardiol. 2007;50(4):327-34.
40. Villanueva FS, Glasheen WP, Sklenar J, Kaul S. Assessment of risk area during coronary occlusion and infarct size after reperfusion with myocardial contrast echocardiography using left and right atrial injections of contrast. Circulation. 1993;88(2):596-604.
41. Villanueva FS, Glasheen WP, Sklenar J, Kaul S. Characterization of spatial patterns of flow within the reperfused myocardium by myocardial contrast echocardiography. Implications in determining extent of myocardial salvage. Circulation. 1993;88(6):2596-606.
42. Funaro S, La Torre G, Madonna M et al. Incidence, determinants, and prognostic value of reverse left ventricular remodelling after primary percutaneous coronary intervention: results of the Acute Myocardial Infarction Contrast Imaging (AMICI) multicenter study. Eur Heart J. 2009;30(5):566-75. One in a series of reports from the AMICI study. Improvement in microvessel perfusion (measured by MCE) during the first week after AMI was a strong marker for reverse LV remodeling and favourable longterm outcome.
43. Kaufmann BA, Lindner Jr. Molecular imaging with targeted contrast ultrasound. Curr Opin Biotechnol. 2007;18(1):11-6. (Pubitemid 46237740)
44. Marwick TH, Narula J. Contrast echocardiography: overachievement in research, under-Achievement in practice? JACC Cardiovasc Imaging. 2010;3(2):224-5.
45. White SK, Sado DM, Flett AS, Moon JC. Characterising the myocardial interstitial space: the clinical relevance of noninvasive imaging. Heart. 2012;98(10):773-9.
46. Judd RM, Lugo-Olivieri CH, Arai M, et al. Physiological basis of myocardial contrast enhancement in fast magnetic resonance images of 2-day-old reperfused canine infarcts. Circulation. 1995;92(7):1902-10.
47. Wu KC, Kim RJ, Bluemke DA, et al. Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. J Am Coll Cardiol. 1998;32(6):1756-64.
48. Manka R, Jahnke C, Kozerke S, et al. Dynamic 3-dimensional stress cardiac magnetic resonance perfusion imaging: detection of coronary artery disease and volumetry of myocardial hypoenhancement before and after coronary stenting. J Am Coll Cardiol. 2011;57(4):437-44.
49. Motwani M, Maredia N, Fairbairn TA, et al. High-resolution versus standard-resolution cardiovascular MR myocardial perfusion imaging for the detection of coronary artery disease. Circ Cardiovasc Imaging. 2012;5(3):306-13.
50. Simonetti OP, Kim RJ, Fieno DS, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001;218(1):215-23.
51. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100(19):1992-2002.
52. Nijveldt R, Hofman MB, Hirsch A, et al. Assessment of microvascular obstruction and prediction of short-Term remodeling after acute myocardial infarction: cardiac MR imaging study. Radiology. 2009;250(2):363-70.
53. Yan AT, Gibson CM, Larose E, et al. Characterization of microvascular dysfunction after acute myocardial infarction by cardiovascular magnetic resonance first-pass perfusion and late gadolinium enhancement imaging. J Cardiovasc Magn Reson. 2006;8(6):831-7. (Pubitemid 44630053)
54. Mather AN, Lockie T, Nagel E, et al. Appearance of microvascular obstruction on high resolution first-pass perfusion, early and late gadolinium enhancement CMR in patients with acute myocardial infarction. J Cardiovasc Magn Reson. 2009;11:33.
55. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97 (8):765-72.
56. Hombach V, Grebe O, Merkle N, et al. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J. 2005;26(6):549-57.
57. Nijveldt R, Beek AM, Hirsch A, et al. Functional recovery after acute myocardial infarction: comparison between angiography, electrocardiography, and cardiovascular magnetic resonance measures of microvascular injury. J Am Coll Cardiol. 2008;52 (3):181-9. (Pubitemid 351915778)
58. Orn S, Manhenke C, Greve OJ, et al. Microvascular obstruction is a major determinant of infarct healing and subsequent left ventricular remodelling following primary percutaneous coronary intervention. Eur Heart J. 2009;30(16):1978-85.
59. Weir RAP, Murphy CA, Petrie CJ, et al. Microvascular obstruction remains a portent of adverse remodeling in optimally treated patients with left ventricular systolic dysfunction after acute myocardial infarction. Circ Cardiovasc Imaging. 2010;3(4):360-7.
60. Wong DT, Leung MC, Richardson JD et al. Cardiac magnetic resonance derived late microvascular obstruction assessment post ST-segment elevation myocardial infarction is the best predictor of left ventricular function: a comparison of angiographic and cardiac magnetic resonance derived measurements. Int J Cardiovasc Imaging. 2012.
61. Bruder O, Breuckmann F, Jensen C, et al. Prognostic impact of contrast-enhanced CMR early after acute ST segment elevation myocardial infarction (STEMI) in a regional STEMI network: results of the "Herzinfarktverbund Essen". Herz. 2008;33(2):136-42.
62. Cochet AA, Lorgis L, Lalande A, et al. Major prognostic impact of persistent microvascular obstruction as assessed by contrastenhanced cardiac magnetic resonance in reperfused acute myocardial infarction. Eur Radiol. 2009;19(9):2117-26.
63. de Waha S, Desch S, Eitel I et al. Impact of early vs. late microvascular obstruction assessed by magnetic resonance imaging on long-Term outcome after ST-elevation myocardial infarction: a comparison with traditional prognostic markers. Eur Heart J. 2010;31(21):2660-8. The largest imaging study of outcome in the presence of MVO, involving 438 patients. The presence of late MVO was shown to be a strong independent predictor for a composite endpoint (death, non-fatal myocardial re-infarction, and congestive heart failure), providing the strongest support that this is the optimal time point for the measurement of MVO by CMR.
64. Wu KC. Functional and clinical impact of microvascular obstruction in acute MI. 2011 SCMR/EuroCMR Joint Scientific Sessions; 2011; Nice, France. http://www.scmr.org/Education/CMR-online-video-on-demand-lectures.html.
65. Rochitte CE, Lima JA, Bluemke DA, et al. Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. Circulation. 1998;98(10):1006-14.
66. Larose E, Rodes-Cabau J, Pibarot P, et al. Predicting late myocardial recovery and outcomes in the early hours of ST-segment elevation myocardial infarction traditional measures compared with microvascular obstruction, salvaged myocardium, and necrosis characteristics by cardiovascular magnetic resonance. J Am Coll Cardiol. 2010;55(22):2459-69.
67. Bekkers SC, Backes WH, Kim RJ, et al. Detection and characteristics of microvascular obstruction in reperfused acute myocardial infarction using an optimized protocol for contrast-enhanced cardiovascular magnetic resonance imaging. Eur Radiol. 2009;19 (12):2904-12.
68. Bekkers SC, Yazdani SK, Virmani R, Waltenberger J. Microvascular obstruction: underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol. 2010;55(16):1649-60.
69. Xu J, Song YB, Hahn JY et al. Comparison of magnetic resonance imaging findings in non-ST-segment elevation versus STsegment elevation myocardial infarction patients undergoing early invasive intervention. Int J Cardiovasc Imaging. 2011.
70. Cochet A, Lalande A, Lorgis L, et al. Prognostic value of microvascular damage determined by cardiac magnetic resonance in non ST-segment elevation myocardial infarction: comparison between first-pass and late gadolinium-enhanced images. Invest Radiol. 2010;45(11):725-32.
71. Eitel I, Desch S, de Waha S, et al. Sex differences in myocardial salvage and clinical outcome in patients with acute reperfused STelevation myocardial infarction: advances in cardiovascular imaging. Circ Cardiovasc Imaging. 2012;5(1):119-26.
72. de Waha S, Desch S, Eitel I et al. Relationship and prognostic value of microvascular obstruction and infarct size in STelevation myocardial infarction as visualized by magnetic resonance imaging. Clin Res Cardiol. 2012.
73. Schofer J, Montz R, Mathey DG. Scintigraphic evidence of the "no reflow" phenomenon in human beings after coronary thrombolysis. J Am Coll Cardiol. 1985;5(3):593-8. (Pubitemid 15141964)
74. Jeremy RW, Links JM, Becker LC. Progressive failure of coronary flow during reperfusion of myocardial infarction: documentation of the no reflow phenomenon with positron emission tomography. J Am Coll Cardiol. 1990;16(3):695-704.
75. Galiuto L, Natale L, Leccisotti L, et al. Non-invasive imaging of microvascular damage. J Nucl Cardiol. 2009;16(5):811-31.
76. Kondo M, Nakano A, Saito D, Shimono Y. Assessment of "microvascular no-reflow phenomenon" using technetium-99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction. J Am Coll Cardiol. 1998;32(4):898-903.
77. Hamada S, Nakamura S, Sugiura T, et al. Early detection of the no-reflow phenomenon in reperfused acute myocardial infarction using technetium-99m tetrofosmin imaging. Eur J Nucl Med. 1999;26(3):208-14.
78. Sahin M, Basoglu T, Canbaz F, et al. The value of the TIMI frame count method in the diagnosis of coronary no-reflow: a comparison withmyocardial perfusion SPECTin patients with acutemyocardial infarction. Nucl Med Commun. 2002;23(12):1205-10.
79. Olszowska M, Tracz W, Przewlocki T, et al. The value of myocardial contrast echocardiography compared with SPECT in detecting myocardial perfusion abnormalities in patients with anterior acute myocardial infarction. Kardiol Pol. 2004;60 (1):27-38.
80. Umemura S, Nakamura S, Sugiura T, et al. The effect of verapamil on the restoration of myocardial perfusion and functional recovery in patients with angiographic no-reflow after primary percutaneous coronary intervention. Nucl Med Commun. 2006;27(3):247-54.
81. Bax JJ, Fath-Ordoubadi F, Boersma E, et al. Accuracy of PET in predicting functional recovery after revascularisation in patients with chronic ischaemic dysfunction: head-To-head comparison between blood flow, glucose utilisation and water-perfusable tissue fraction. Eur J Nucl Med. 2002;29(6):721-7.
82. Uren NG, Crake T, Lefroy DC, et al. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction. N Engl J Med. 1994;331(4):222-7. (Pubitemid 24226679)
83. Y-Rit J, Fishbein MC, Lando U, et al. The relationship of vascular injury and myocardial hemorrhage to necrosis after reperfusion. Circulation. 1980;62(6):1274-9. (Pubitemid 11217196)
84. Garcia-Dorado D, Theroux P, Solares J, et al. Determinants of hemorrhagic infarcts. Histologic observations from experiments involving coronary occlusion, coronary reperfusion, and reocclusion. Am J Pathol. 1990;137(2):301-11.
85. Ganame J, Messalli G, Dymarkowski S, et al. Impact of myocardial haemorrhage on left ventricular function and remodelling in patients with reperfused acute myocardial infarction. Eur Heart J. 2009;30(12):1440-9.
86. Beek AM, Nijveldt R, van Rossum AC. Intramyocardial hemorrhage and microvascular obstruction after primary percutaneous coronary intervention. Int J Cardiovasc Imaging. 2010;26(1):49-55.
87. Eitel I, Kubusch K, Strohm O et al. Prognostic value and determinants of a hypointense infarct core in T2-weighted cardiac magnetic resonance in acute reperfused ST-elevation-myocardial infarction. Circ Cardiovasc Imaging. 2011;4(4):354-62. This large CMR study carefully described the method used to assess potential IMH associated with MVO. A 'hypointense core' identified on T2-weighted imaging may indicate the presence of IMH, but may also represent MVO without IMH. A worse outcome in such patients nevertheless affirms the need to better understand the pathophysiology, and imaging, of IMH.
88. Basso C, Corbetti F, Silva C, et al. Morphologic validation of reperfused hemorrhagic myocardial infarction by cardiovascular magnetic resonance. Am J Cardiol. 2007;100(8):1322-7. (Pubitemid 47498288)
89. Lotan CS, Bouchard A, Cranney GB, et al. Assessment of postreperfusion myocardial hemorrhage using proton NMR imaging at 1.5 T. Circulation. 1992;86(3):1018-25.
90. Cannan C, Eitel I, Hare J, et al. Hemorrhage in the myocardium following infarction. JACC Cardiovasc Imaging. 2010;3(6):665-8.
91. Kumar A, Green JD, Sykes JM, et al. Detection and quantification of myocardial reperfusion hemorrhage using T2-weighted CMR. JACC Cardiovasc Imaging. 2011;4(12):1274-83.
92. Mather AN, Fairbairn TA, Ball SG et al. Reperfusion haemorrhage as determined by cardiovascular MRI is a predictor of adverse left ventricular remodeling and markers of late arrhythmic risk. Heart. 2011;97(6):453-9. This study used both T2 and T2-weighted CMR imaging techniques to suggest that assessment of IMH by T2.may be more sensitive for the detection of IMH, which may in turn identify a higher risk population for adverse ventricular remodeling.
93. Gerczuk PZ, Kloner RA. An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J Am Coll Cardiol. 2012;59(11):969-78.
94. Hale SL, Dae MW, Kloner RA. Hypothermia during reperfusion limits 'no-reflow' injury in a rabbit model of acute myocardial infarction. Cardiovasc Res. 2003;59(3):715-22.
95. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54(4):281-92.
96. Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol. 1997;30(5):1193-9. (Pubitemid 27501434)
97. Sakuma T, Hayashi Y, Sumii K, et al. Prediction of short-And intermediate-Term prognoses of patients with acute myocardial infarction using myocardial contrast echocardiography one day after recanalization. J Am Coll Cardiol. 1998;32(4):890-7. (Pubitemid 28459575)
98. Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol. 1999;33(3):654-60.
99. Iwakura K, Ito H, Kawano S, et al. Chronic pre-Treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J. 2006;27(5):534-9.
100. Kunichika H, Ben-Yehuda O, Lafitte S, et al. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study. J Am Coll Cardiol. 2004;43(2):276-83.
101. Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with intravenous bolus abciximab application in patients with STelevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation. 2008;118(1):49-57.
102. Thuny F, Lairez O, Roubille F, et al. Post-conditioning reduces infarct size and Edema in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2012;59(24):2175-81.
103. Atar D, Petzelbauer P, Schwitter J, et al. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol. 2009;53(8):720-9.
104. Ludman AJ, Yellon DM, Hasleton J, et al. Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial. Heart. 2011;97(19):1560-5.
105. Payne AR, Berry C, Doolin O et al. Microvascular Resistance Predicts Myocardial Salvage and Infarct Characteristics in STElevationMyocardial Infarction. J Am Heart Assoc. 2012, In press.